When relaxin-3 is released in the brain, it binds to a target receptor RXFP3—to trigger a variety of signaling responses among the cells, which affect the body's physiological processes.

Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product ...